Oscient Pharmaceuticals Provides Preliminary Revenue Results for the Second Quarter of 2007 (Business Wire via Yahoo! Finance)
WALTHAM, Mass.----Oscient Pharmaceuticals Corporation today announced preliminary revenue results for the second quarter of 2007. The Company expects to record total revenues of approximately $15 - $16 million in the second quarter of 2007, compared to $4.6 million in total revenues in the second quarter of 2006, prior to the acquisition of ANTARA capsules in August 2006.

AtriCure's Isolator(R) Bipolar Ablation Clamp System Receives FDA 510(k) Clearance For Cardiac Use (Medical News Today)
AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative cardiac surgical devices, announced today that its Isolator(R) bipolar ablation clamp system has received 510(k) clearance from the Food and Drug Administration (FDA) for the ablation of cardiac tissue. [click link for full article]